NA
SKYE icon

NewEdge Advisors’s Skye Bioscience SKYE Stock Holding History

NewEdge Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$2 – 4178
2025
Q1 		$2 Hold
1
– – ﹤0.01% 3944
2024
Q4 		$3 Buy
+1
New +$4 ﹤0.01% 3892

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

NewEdge Advisors's SKYE Position: Q2 2025 in Review

NewEdge Advisors sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 1 share — an estimated $2 sold.

NewEdge Advisors first reported a position in SKYE in Q4 2024 and held it in 2 quarters. The position peaked at $3 in Q4 2024. 58 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • NewEdge Advisors reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • NewEdge Advisors sold 1 Skye Bioscience share in Q2 2025, an estimated $2.
  • NewEdge Advisors first reported a position in Skye Bioscience in Q4 2024 and held it in 2 quarters.
  • NewEdge Advisors's Skye Bioscience position peaked at $3 in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.